Revvity Inc Stock Price, News & Analysis

Revvity (NYSE: RVTY) will present at three investor conferences in November–December 2025 with senior executives providing company updates and strategic priorities.

Schedule: UBS Global Healthcare Conference on Nov 10, 2025 at 8:00 a.m. ET (Max Krakowiak, SVP & CFO); Jefferies London Healthcare Conference on Nov 18, 2025 at 2:00 p.m. GMT (Max Krakowiak); and Citi Global Healthcare Conference on Dec 2, 2025 at 9:00 a.m. ET (Prahlad Singh, president & CEO).

Events are fireside chats; live audio webcasts will stream on the company Events page and replays will be posted to Revvity investor relations for at least 30 days.

Revvity (NYSE: RVTY) reported Q3 2025 results for the quarter ended September 28, 2025: revenue $699M (2% reported growth, 1% organic), GAAP EPS $0.40, and adjusted EPS $1.18. GAAP operating margin was 11.7%; adjusted operating margin was 26.1%. By segment, Life Sciences revenue was $343M (flat organic) and Diagnostics revenue was $356M (organic +2%).

The company reaffirmed 2025 organic growth guidance of 2%–4%, raised adjusted EPS guidance to $4.90–$5.00, and authorized a new $1 billion two-year share repurchase program. Management cited strategic partnerships and innovation as drivers for future execution.

Revvity (NYSE: RVTY) declared a regular quarterly dividend of $0.07 per share. The dividend is payable on February 6, 2026 to shareholders of record at the close of business on January 16, 2026.

Revvity (NYSE: RVTY) released its 2025 Impact Report, "Progress with Purpose: Science and Sustainability," summarizing sustainability, social and governance progress through 2024.

Key highlights include a 6% year-over-year reduction in Scope 1 and 2 emissions in 2024 (a 14% cumulative cut since 2022), 49% of non-hazardous waste diverted from landfills in 2024 (exceeding a 40% by-2027 target), and an AAA MSCI ESG rating. The report notes completion of a double materiality assessment and expansion of Revvity Access STEM Scholarships to global universities. The company also earned Great Place to Work recognition in multiple countries.

Revvity (NYSE: RVTY) will release its third-quarter 2025 financial results before market open on Monday, October 27, 2025. The company will hold a conference call the same day at 8:00 a.m. ET to discuss the results.

Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the call. A live audio webcast will be available in the Investors section of the company's website for access.

Revvity (NYSE:RVTY) has announced a significant program to expand its type 1 diabetes (T1D) testing capabilities, partnering with Sanofi. The initiative includes developing a T1D 4-plex in vitro diagnostic (IVD) assay based on their existing 3-plex research-use assay.

The program aims to enable population-scale screening for early-stage T1D using Revvity's GSP® instrument with both capillary dried blood spot and venous specimens. The company plans regulatory submissions to the U.S. FDA, IVDR, and other major jurisdictions. Additionally, Revvity will expand its laboratory network globally to increase access to its existing research-use product, currently offered as an LDT at their CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh.

This initiative addresses a significant medical need, as over 9 million people worldwide live with T1D, with more than 500,000 new cases diagnosed annually, 90% without family history.

Revvity (NYSE:RVTY) has launched Living Image™ Synergy AI, a groundbreaking multimodal analysis software for in vivo imaging research. The platform unifies data analysis across optical, microCT, and ultrasound modalities, integrating advanced AI capabilities to enhance preclinical imaging analysis.

The software aims to streamline workflows by centralizing analysis tools, automating image segmentation, and providing intuitive co-registration capabilities. Key features include automated ROI quantification, reduced manual tasks, and enhanced reproducibility across studies. The platform will be showcased at the WMIC conference in Anchorage, Alaska from September 29 to October 3, 2025.

Revvity (NYSE:RVTY) has announced a strategic collaboration with Profluent to enhance its Pin-point™ base editing platform with AI-engineered enzymes. The partnership combines Profluent's AI-designed proteins with Revvity's established technology to create a more precise and efficient gene editing toolkit.

The enhanced Pin-point platform achieves single nucleotide precision without bystander editing and requires ultra-low amounts of deaminase while maintaining clinical editing levels. This collaboration follows Revvity's successful integration of Profluent's OpenCRISPR™ nuclease into the Pin-point system, previously published in Nature.

The new system will be available through bundled licensing, aiming to accelerate the development of gene therapies. Revvity will showcase this technology at the ESGCT 2025 Annual Congress in Seville, Spain.

Revvity (NYSE:RVTY) has announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina's Research Triangle. The state-of-the-art facility consolidates R&D teams specializing in software, hardware, applied biology, machine learning, optical, microCT, and ultrasound technologies.

The center showcases Revvity's latest innovations including the IVIS™ optical imaging systems, Quantum™ GX3 microCT system, Vega™ automated preclinical ultrasound system, and VivoJect™ Image-Guided Injection System. The facility aims to accelerate innovation in disease research workflows and advance next-generation imaging instruments while offering live demos and training opportunities for visitors.